These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25846744)

  • 1. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
    Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
    Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
    Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
    Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
    Xing L; Lv HT; Liu SG; Wang WB; Zhang TF; Liu JH; Bian W
    Scand J Gastroenterol; 2021 Aug; 56(8):914-919. PubMed ID: 34165373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
    Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
    World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
    Redjal N; Chan JA; Segal RA; Kung AL
    Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.
    Guo ZJ; Yang L; Qian F; Wang YX; Yu X; Ji CD; Cui W; Xiang DF; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
    Oncotarget; 2016 Apr; 7(15):20999-1012. PubMed ID: 27007162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
    Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of CXCR4 Blockade on the Survival of Rat Brain Cortical Neurons.
    Merino JJ; Garcimartín A; López-Oliva ME; Benedí J; González MP
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
    Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
    Wang J; Tannous BA; Poznansky MC; Chen H
    Pharmacol Res; 2020 Sep; 159():105010. PubMed ID: 32544428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma.
    Jeong WJ; Choi IJ; Park MW; An SY; Jeon EH; Paik JH; Sung MW; Ahn SH
    J Clin Pathol; 2014 Nov; 67(11):992-8. PubMed ID: 25118295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
    Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
    Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.